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Summary
The autosomal dominant cerebellar ataxias (ADCAs)
are a clinically and genetically heterogeneous group of
disorders. The clinical symptoms include cerebellar dys-
function and associated signs from dysfunction in other
parts of the nervous system. So far, five spinocerebellar
ataxia (SCA) genes have been identified: SCA1, SCA2,
SCA3, SCA6, and SCA7. Loci for SCA4 and SCA5 have
been mapped. However, approximately one-third of
SCAs have remained unassigned. We have identified a
Mexican American pedigree that segregates a new form
of ataxia clinically characterized by gait and limb ataxia,
dysarthria, and nystagmus. Two individuals have sei-
zures. After excluding all known genetic loci for linkage,
we performed a genomewide search and identified link-
age to a 15-cM region on chromosome 22q13. A max-
imum LOD score of 4.3 (recombination fraction 0) was
obtained for D22S928 and D22S1161. This distinct
form of ataxia has been designated “SCA10.” Antici-
pation was observed in the available parent-child pairs,
suggesting that trinucleotide-repeat expansion may be
the mutagenic mechanism.
Introduction
The autosomal dominant cerebellar ataxias (ADCAs) are
a clinically heterogeneous group of disorders character-
ized by ataxia, dysarthria, dysmetria, and intention
tremor (Harding 1982, 1993). All ADCAs involve some
degree of cerebellar dysfunction and a varying degree of
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signs from other components of the nervous system.
There have been several schemes of classification of the
syndromes into different types based on clinical and
pathological criteria. One commonly accepted clinical
classification (Harding 1993) divides ADCAs into three
different groups based on the presence or absence of
associated symptoms such as brain-stem signs or reti-
nopathy: presence of pyramidal and extrapyramidal
symptoms and ophthalmoplegia (ADCA I), presence of
retinopathy (ADCA II), and absence of the associated
signs (ADCA III).
Genetic-linkage studies and molecular analysis of the
gene mutations have revealed that ADCAs are geneti-
cally heterogeneous even within the various subtypes.
ADCA I is caused by mutations in three different genes:
those for spinocerebellar ataxia (SCA) types 1–3
(SCA1–SCA3) (Orr et al. 1993; Kawaguchi et al. 1994;
Imbert et al.1996; Pulst et al. 1996; Sanpei et al. 1996).
ADCA II is caused by mutations in SCA7 (David et al.
1997; Del-Favero et al.1998; Koob et al. 1998). All mu-
tations involve a trinucleotide-repeat expansion in the
coding region of the gene. ADCA III is a predominant
cerebellar phenotype and has been described in one large
pedigree with linkage to chromosome 11 and has been
designated “SCA5” (Ranum et al. 1994). In addition,
CAG expansions in the CACNl gene on chromosome
19 cause SCA6 (Zhuchenko et al. 1997) and, especially
in the lower pathological repeat range, cause a predom-
inantly cerebellar phenotype.
Elsewhere we have identified a four-generation Mex-
ican pedigree that segregates a distinct form of SCA
(Grewal et al. 1998). The clinical phenotypes are char-
acterized by predominantly cerebellar symptoms and
signs and thus fall within the ADCA III clinical classi-
fication. Two affected individuals also had seizures, but
it could not be determined whether these were caused
by focal CNS lesions or were part of the degenerative
phenotype. All known SCA loci, as well as mutations in
the DRPLA gene, were excluded by direct mutation or
genetic-linkage analysis. We now report the results of a
genomewide search for linkage and assignment of
SCA10 to human chromosome 22q.
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Table 1
Clinical Characteristics of Patients with SCA10
Symptom(s) or sign(s)
Incidence
(%)
Truncal and gait ataxia 100
Dysarthria 100
Nystagmus 100
Seizures 20
Pyramidal or basal-ganglion signs 0
Dementia 0
Ophthalmoplegia or visual loss 0
Sensory loss 0
Subjects and Methods
The subjects were recruited from a four-generation
Mexican family in which a distinct form of autosomal
dominant SCA was ascertained, clinically characterized
by gait and limb ataxia, dysarthria, and nystagmus. Af-
ter informed consent (approved by the institutional re-
view boards of the University of Southern California and
Cedars-Sinai Medical Center) was obtained, blood sam-
ples were drawn from the 20 available family mem-
bers—10 affected individuals and 10 unaffected indi-
viduals. Genomic DNA samples were extracted
according to standard protocols (Puregene; Gentra
Systems).
We performed a genomewide search for the genetic
locus underlying this new form of SCA. A total of 386
fluorescent-tagged microsatallite markers in the Human
Screening Set version 8/8aRG were purchased from Re-
search Genetics. These markers cover the entire genome,
with an average 10-cM interval.
After mapping of the SCA10 locus, we searched the
Sanger Centre sequence database for potential poly-
morphic genetic markers and designed primers by using
the Primer 3 program of the Whitehead Institute for
Biomedical Research/MIT Center for Genome Research.
One simple-tandem-repeat marker in plasmid-artificial-
chromosome (PAC) clone DJ522J7 was informative in
the pedigree and was amplified by the following
primers: CADJ522 A (5′-aacacggccaaatctcaaac-3′) and
CADJ522B (5′-gagggtagaatcaactccatgc-3′).
PCR was performed in a 20-ml reaction containing
100 ng of genomic DNA template, 100 pmol of each
primer, 2.5 mM each dNTP, 2.5 mM MgCl2, and 1 unit
of Gold Taq polymerase (Perkin-Elmer) in the 10# buf-
fer provided by the vendor. The reaction conditions were
as follows: initial denaturation at 94C for 2 min; 30
cycles of denaturation at 94C for 45 s, annealing at
55C for 45 s, and extension at 72C for 60 s; and a
final extension at 72C for 7 min (all steps were com-
pleted within a 96-well PTC 100 thermal cycler [M.J.
Research]). The PCR products were then analyzed in a
6% denaturing polyacrylamide gel, by an Applied Bio-
systems (ABI) 373 automated DNA sequencer. The
markers in the same panel designed by the vendor were
pooled and analyzed in one lane. Allele numbers were
determined according to the internal standard (Tamra
350; Perkin Elmer/ABI). Both Genescan and Genotyper
software packages (Perkin-Elmer/ABI) were utilized for
the computer analysis to transfer data from image to
digital numbers.
Two-point linkage analysis was performed by use of
the linkage 5.1 package (Lathrop and Lalouel 1984),
under the assumption of autosomal dominant inheri-
tance and a disease frequency of 1/100,000. The allele
frequencies were assumed to be equal for each marker.
Penetrance was assumed to be .95. In separate calcu-
lations, penetrance was set at .99 in generation II, .90
in generation III, and .80 in generation 4, without sig-
nificant changes in LOD scores. Similarly, changes in
allele frequencies did not have a significant effect on
LOD scores.
Results
A summary of the clinical phenotype in this family is
shown in table 1 and is notable for the absence of symp-
toms or signs in other CNS structures, except for the
presence of seizures in two individuals. To map this new
SCA, we undertook a genomewide search for linkage.
After testing 47 markers, we detected a positive LOD
score of 1.82, at recombination fraction [v] .11, with
marker D22S683.
We explored this result further by usingmarkers flank-
ing D22S683, to test linkage. Markers proximal to
D22S683 recognized additional recombination events
(data not shown), whereas several markers distal to
D22S683 yielded higher LOD scores (table 2). Markers
D22S928 and D22S1161 were informative for each mei-
osis and yielded the highest LOD scores: 4.30. Changing
the penetrance assumptions or allele frequencies had
only minimal effects on the observed LOD scores (data
not shown). Even at a penetrance of .50, all maximum
LOD score (Zmax) values were still 13.
No telomeric recombination events were identified for
chromosome 22 markers available from the public ge-
netic map. We therefore searched for extended CA re-
peats in the genomic sequence database at the Sanger
Centre. Several such repeats were identified in PAC
clones mapping telomeric on chromosome 22. We tested
these in the pedigree described above and in 10 unrelated
individuals. One marker, CADJ522, which was identi-
fied from clone DJ522J7, was informative in the pedigree
and detected one recombination event in an affected in-
dividual. According to the physical map from the Sanger
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Figure 1 Ideogram of chromosome 22, showing markers linked
to SCA10, as well as their relative genetic or physical distances (from
Genome Database). Marker CADJ522 was identified by searching the
Sanger Centre database. The four PAC clones between marker
D22S526 and CADJ522 have all been completely sequenced and span
a distance of 520 kb.
Table 2
Two-Point LOD Scores for SCA10 versus Markers in chromosome 22q13
LOCUS
LOD SCORE AT v 
Zmax MAXIMUM v0 .01 .05 .10 .20 .30 .40
D22S683 3.6 1.02 1.68 1.82 1.62 1.17 .56 1.82 .11
D22S1140 3.96 1.87 2.32 2.29 1.90 1.31 .60 2.34 .07
D22S274 3.98 3.92 3.65 3.29 2.54 1.70 .79 3.98 0
D22S928 4.30 4.22 3.94 3.56 3.16 1.86 .87 4.30 0
D22S1161 4.30 4.22 3.94 3.56 3.16 1.86 .87 4.30 0
D22S526 2.25 2.21 2.04 1.82 1.37 .87 .34 2.25 0
CADJ522 4.65 .19 .77 .90 .86 .65 .36 .92 .13
Centre, there are three overlapping and completely se-
quenced PAC clones between clone DJ522J7 and clone
DJ170A21, which contains the sequence for genetic
marker D22S526, the last distal marker available from
the public genetic map. The physical distance between
D22S526 and CADJ522 is ∼520 kb. Thus, the SCA10
candidate region encompasses ∼15 cM flanked proxi-
mally by D22S1140 and distally by CADJ522 (fig. 1).
Haplotypes for the markers are shown in figure 2. For
D22S683, the first marker showing linkage in the initial
genome scan, two recombination events were detected
in individual IV:1 (affected) and in individual III:7 (un-
affected). For D22S1140, a recombination event was
identified in individual IV:1; and, for CADJ522, a re-
combination event was identified in individual IV:2. Both
of these individuals are clearly affected.
Anticipation was observed in the age at onset in this
pedigree (fig. 2). In generation III, the average age at
onset was 34.2 years, and in generation IV it was 14.5
years; the difference was significantly different (P !
). In this pedigree, the Penrose coefficient calcu-.0002
lated for individuals in generations III and IV was .84,
which is similar to the coefficient calculated for pedigrees
with myotonic dystrophy (Penrose 1948).
Discussion
We have identified a new SCA locus on human chro-
mosome 22; in addition to five identified autosomal
dominant ataxia genes and two SCA loci, we have here
presented evidence for an additional ataxia locus, which
we have designated “SCA10.” On the basis of the phe-
notype in this SCA10 family, as summarized in table 1,
SCA10 is associated with an ADCA III phenotype.
ADCA III refers to a phenotype that is purely or pre-
dominantly cerebellar in nature. However, additional
families linking to the SCA locus will need to be assessed
to determine the phenotypic spectrum of SCA10, espe-
cially with regard to the presence of seizures. For ex-
ample, SCA6 phenotypes vary from ADCA type III for
moderate expansions to an ADCA type I phenotype with
longer CAG expansions.
It is interesting to note that no new SCA loci have
been mapped by genetic-linkage analysis during the past
3 years. The last chromosomal assignment of an ADCA
was in 1995, when SCA7 was mapped to human chro-
mosome 3p (Benomar et al. 1995; Gouw et al. 1995;
Holmberg et al. 1995; David et al. 1996; Krols et al.
1997). This is despite the fact that one-third of ADCA
pedigrees worldwide have not been assigned to known
genes or loci (Ranum et al. 1995; Geschwind et al. 1997;
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Figure 2 Haplotypes for seven chromosome 22 markers in the Mexican-American SCA10 pedigree. Note the recombination events in
III:7, IV:1, and IV:2. Affected individuals are represented by blackened symbols, unaffected individuals are represented by unblackened symbols,
and the diagonal slash through the symbol for II:2 denotes that this individual is deceased. Ages at onset are given at the upper right of the
symbols.
Riess et al. 1997; and Schols et al. 1997). It is possible
that, in the existing pedigrees, significant anticipation or
disease severity has resulted in a pedigree too small for
genetic-linkage analysis. Alternatively, significant seg-
regation distortion could influence pedigree size. The
identification of the SCA10 locus now makes it possible
to examine linkage in these smaller pedigrees. We have
since tested two unassigned smaller pedigrees from the
University of California, Los Angeles, clinic. Both were
not linked to the SCA10 locus (data not shown).
Except for questionable anticipation in SCA4 (Flan-
igan et al. 1996), all dominant SCAs have shown antic-
ipation. The analysis of a pedigree for the presence of
anticipation may be difficult, because, in the youngest
generation, asymptomatic gene carriers who have not
yet developed the disease may bias ascertainment. After
close flanking markers have been identified, this bias can
be excluded. Indeed, in the Mexican SCA10 pedigree,
linkage analysis confirmed that all individuals with the
disease haplotype had already developed symptoms. An-
ticipation in this pedigree appears to be marked and
occurred at age 18–23 years (fig. 2). Unlike SCA5, in
which the most dramatic examples of anticipation were
seen with maternal transmissions, anticipation in SCA10
appears to occur in paternal transmissions, although,
clearly, a larger number of transmissions need to be stud-
ied. These observations suggest that SCA10, like the
other SCAs, may be caused by an unstable trinucleotide
repeat. This could be tested by the repeat expan-
sion–detection method (Schalling et al. 1993) or by use
of a monoclonal antibody that detects expanded glu-
tamine repeats (Trottier et al. 1995). Both methods,
however, require significant polyglutamine expansions.
The 15-cM region on chromosome 22 covers an es-
timated 9-million-bp physical distance, according to the
physical map from the Sanger Centre. Despite this rather
large physical distance, positional cloning of SCA10 can
be achieved. First, this part of the genome has been in-
tensively investigated by the Human Genome Project. So
far, ∼90 clones (bacterial artificial chromosome, PAC,
and cosmid) have been identified that cover this entire
region, leaving few gaps. Of 90 clones, half have been
completely sequenced, and many are partially se-
quenced. Second, both the observation of anticipation
in the age at onset in the pedigree and the fact that all
the SCA mutations thus far identified involve a trinu-
598 Am. J. Hum. Genet. 64:594–599, 1999
cleotide-repeat expansion suggest that SCA10 may con-
tain a trinucleotide repeat within its sequence. Identifi-
cation of another SCA gene will greatly facilitate
diagnosis of SCA patients and also will have an impact
on our understanding of the molecular mechanisms un-
derlying ADCAs.
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